KRAS Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings

BACKGROUND: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to epidermal growth factor receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake and utili...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Webster, Jennifer, Kauffman, Tia L., Feigelson, Heather Spencer, Pawloski, Pamala A., Onitilo, Adedayo A., Potosky, Arnold L., Cross, Deanna, Meier, Paul R., Mirabedi, Anousheh S., Delate, Thomas, Daida, Yihe, Williams, Andrew E., Alexander, Gwen L., McCarty, Catherine A., Honda, Stacey, Kushi, Lawrence H., Goddard, Katrina A.B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567775/
https://ncbi.nlm.nih.gov/pubmed/23155138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-12-0545
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky